Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart ...
In atopic dermatitis, the first interleukin-22 inhibitor to reach late clinical trials is showing uncommonly broad suppression of biomarkers associated with disease activity.
Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...
A new vaccine targeting triple-negative breast cancer (TNBC) has shown promising results in its first human clinical trial.
Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...
Researchers found that fructose can prime immune cells to overreact to bacterial toxins. In healthy adults, ...
Experts at SICP 2025 outline how molecular mechanisms and bedside assessments can guide personalised treatment for ...
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase ...
An experimental vaccine targeting aggressive triple-negative breast cancer (TNBC) has shown encouraging early results in ...
As previously announced, Medicenna will present updated clinical data from the ABILITY-1 Phase 1/2 Study, evaluating MDNA11 as a monotherapy and in combination with pembrolizumab, on December 10 th at ...
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS ...
This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback